Clinic
North Texas - Mca LLC
North Texas - Mca LLC was paid $8.21M by Medicaid between Sep 2020 and Dec 2024, across 46 billing codes. Its largest line is 99283, emergency room visit (moderate) — 53% of everything it billed.
33Billing provider infoNORTH TEXAS - MCA LLC
FORT WORTH, TX 76177
FORT WORTH, TX 76177
33aNPI1871911016assigned 04/04/2014
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$8.21M
24GClaims99,891
24DCodes billed46
24AFirst – last monthSep 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#56 of 320
Median peer was paid$205K
This provider vs. median40×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 599 | $60K | |
| 2021 | 11,632 | $947K | |
| 2022 | 29,013 | $2.29M | |
| 2023 | 36,904 | $3.29M | |
| 2024incomplete | 21,743 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 53% | 33,827 | 32,646 | $4.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 7,148 | 6,630 | $2.42M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.7% | 12,749 | 9,685 | $305K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 2,306 | 2,228 | $300K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 3,006 | 2,917 | $186K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 4,044 | 3,876 | $166K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 3,888 | 3,682 | $95K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,388 | 3,262 | $67K |
| 87430 | <1% | 2,453 | 2,378 | $49K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,135 | 1,053 | $47K |
| 80053 | Comprehensive metabolic panel | <1% | 3,868 | 3,539 | $46K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 661 | 617 | $39K |
34 more codes
| 87070 | <1% | 3,107 | $39K | |
| 85027 | <1% | 5,997 | $27K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 757 | $20K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,437 | $12K |
| 81001 | <1% | 3,423 | $10K | |
| 76801 | <1% | 61 | $6K | |
| 81025 | <1% | 762 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 100 | $5K |
| 84484 | <1% | 574 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $4K |
| 83690 | <1% | 1,067 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 768 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,221 | $2K |
| 99285 | Emergency room visit (most serious) | <1% | 12 | $2K |
| 87420 | <1% | 131 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 18 | $2K |
| 84702 | <1% | 135 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 307 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 15 | $1K |
| 87807 | <1% | 58 | $920.55 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 115 | $777.32 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 613 | $720.00 |
| 81003 | <1% | 116 | $710.10 | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13 | $652.21 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 92 | $565.01 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 26 | $294.92 |
| 83880 | <1% | 45 | $201.95 | |
| 86901 | <1% | 76 | $150.60 | |
| 85610 | <1% | 116 | $98.02 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 59 | $9.39 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 26 | $8.72 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 14 | $0.00 |
| A9270 | Non-covered item or service | 0% | 32 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 84 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVILLAGRAN, ANTHONY (CFO)